JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March19, 2018, the Board of Directors (the “Board”) of the Company appointed Richard Messina to the Board, effective March19, 2018. Richard Messina will hold office until the date of the annual meeting of stockholders following the year ending December31, 2017 or until his earlier death, resignation or removal. The Board has determined that Richard Messina satisfies the definition of “independent” director, including without limitation the applicable requirements of the NASDAQ Listing Rules and the Securities Exchange Act of 1934, as amended (collectively, “Applicable Requirements”).

The Board will grant Richard Messina an initial restricted stock unit award with a grant value of $67,500. Such award will vest ratably over three years in annual installments. As a non-employee director, Richard Messina will receive compensation in the same manner as the Company’s other non-employee directors, including an annual retainer of $40,000 for service on the Board. Additionally, in connection with Richard Messina’s appointment to the Board, the Company and Richard Messina will enter into an indemnification agreement in substantially the same form that the Company has entered into with each of the Company’s existing directors. The form of such indemnification agreement was previously filed by the Company as an exhibit to its annual report on Form 10-K (File No.001-10352) for the year ended December31, 2003, filed on March15, 2004 with the Securities and Exchange Commission.

There are no arrangements or understandings between Richard Messina and any other person to which he was appointed as a member of the Board. There are no family relationships between Richard Messina, on the one hand, and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer, on the other. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Richard Messina and the Company.

About JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP)

Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.